Astria Therapeutics (ATXS) Research & Development: 2013-2018
Historic Research & Development for Astria Therapeutics (ATXS) over the last 6 years, with Dec 2018 value amounting to $17.0 million.
- Astria Therapeutics' Research & Development fell 8.27% to $3.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $17.0 million, marking a year-over-year decrease of 8.78%. This contributed to the annual value of $17.0 million for FY2018, which is 8.78% down from last year.
- Latest data reveals that Astria Therapeutics reported Research & Development of $17.0 million as of FY2018, which was down 8.78% from $18.7 million recorded in FY2017.
- Astria Therapeutics' 5-year Research & Development high stood at $25.4 million for FY2016, and its period low was $15.7 million during FY2014.
- For the 3-year period, Astria Therapeutics' Research & Development averaged around $20.4 million, with its median value being $18.7 million (2017).
- In the last 5 years, Astria Therapeutics' Research & Development soared by 46.82% in 2015 and then dropped by 26.59% in 2017.
- Yearly analysis of 5 years shows Astria Therapeutics' Research & Development stood at $15.7 million in 2014, then spiked by 46.82% to $23.0 million in 2015, then grew by 10.51% to $25.4 million in 2016, then decreased by 26.59% to $18.7 million in 2017, then dropped by 8.78% to $17.0 million in 2018.